ArticleNucleic acids research2026
SDMap: a comprehensive database of spatial drug perturbation maps.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The arrangement patterns and spatial distribution features of cells within tissues are key regulators of drug actions and cellular responses; however, the specific spatial microenvironment that mediates drug actions and efficacy remains to be elucidated. Here, we introduce SDMap (http://bio-bigdata.hrbmu.edu.cn/SDMap/), a database to dissect the spatial distributions of drug-associated cells and spatial contexts that contribute to drug actions. SDMap establishes connections between 5 490 079 spatial locations (spots/cells) derived from 989 slices of 35 human tissues (including disease-state slices) and 538 419 instances across 33 149 drugs. It also offers 10 user-friendly tools for retrieving and analyzing: (i) associations between drug-associated instances and spatial spots/cells, niches, or cell types; (ii) the influence of spatial drug target activity on drug actions; (iii) drug-associated instances exhibiting highly variable spatial perturbation effects; (iv) the perturbation effects of drug dosage and duration on the spatial microenvironment; (v) spatial differentiation trajectories of drug-perturbed cells; (vi) the impact of spatial cellular functional activity on drug perturbation; (vii) spatial perturbation effect maps of drug combinations; and (viii) 3D maps of drug perturbation effects within spatial tissue contexts. SDMap is anticipated to yield critical insights into how spatial heterogeneity influences drug actions, and serve as a comprehensive database for identifying spatially resolved precision therapy targets and elucidating drug-associated mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.